CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Reminder: On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the ch...
CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
CTS will be transitioning to a new sFTP server for clients who send test request and/or receive...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...